Status:
COMPLETED
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
Lead Sponsor:
Medy-Tox
Conditions:
Overactive Bladder
Eligibility:
FEMALE
20+ years
Phase:
PHASE1
Brief Summary
To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX
Eligibility Criteria
Inclusion
- Female aged more than 20 years
- Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening
Exclusion
- \- Patient not appropriate for participating in this study according to the investigator's opinion
Key Trial Info
Start Date :
December 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 5 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03371342
Start Date
December 13 2017
End Date
September 5 2018
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea